Immunotherapy-Chemo combo before surgery shows promise for advanced ovarian cancer
NCT ID NCT07673835
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether combining two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy before surgery can improve outcomes for people with advanced ovarian cancer. Participants receive 3-4 cycles of the combination, followed by surgery to remove visible tumors, then more chemo after surgery. The study aims to see if this approach extends the time before the cancer progresses. It enrolls 49 adults with stage III or IV ovarian, fallopian tube, or primary peritoneal cancer who are candidates for surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
iparomlimab and tuvonralimab (immunotherapy) plus platinum-based chemotherapy
What this could lead to
If successful, this combination could become a new standard neoadjuvant treatment for advanced ovarian cancer, potentially delaying disease progression.
What could go wrong
This is a small, early-phase trial with no control group, so results may not be definitive. Immunotherapy can cause immune-related side effects, and not all patients may respond.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Obstetrics and Gynecology Hospital of Fudan University
Shanghai, 201101, China
Contact Phone: •••-•••-•••• Email: •••••@•••••